menu
    • menu
    [{"orgOrder":0,"company":"ILiAD Biotechnologies","sponsor":"Knott Partners","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Series D Financing","leadProduct":"Azithromycin","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"ILiAD Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"ILiAD Biotechnologies \/ Knott Partners","highestDevelopmentStatusID":"8","companyTruncated":"ILiAD Biotechnologies \/ Knott Partners"},{"orgOrder":0,"company":"ILiAD Biotechnologies","sponsor":"Emmes Group","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Collaboration","leadProduct":"Bordetella Pertussis Vaccine, Live Attenuated","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"ILiAD Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"ILiAD Biotechnologies \/ Emmes Group","highestDevelopmentStatusID":"8","companyTruncated":"ILiAD Biotechnologies \/ Emmes Group"},{"orgOrder":0,"company":"ILiAD Biotechnologies","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Funding","leadProduct":"Tuberculosis Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"ILiAD Biotechnologies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ILiAD Biotechnologies \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"ILiAD Biotechnologies \/ National Institutes of Health"},{"orgOrder":0,"company":"ILiAD Biotechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Bordetella Pertussis Vaccine, Live Attenuated","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"ILiAD Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"ILiAD Biotechnologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ILiAD Biotechnologies \/ Inapplicable"},{"orgOrder":0,"company":"ILiAD Biotechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Bordetella Pertussis Vaccine, Live Attenuated","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"ILiAD Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"ILiAD Biotechnologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ILiAD Biotechnologies \/ Inapplicable"},{"orgOrder":0,"company":"ILiAD Biotechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Bordetella Pertussis Vaccine, Live Attenuated","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"ILiAD Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"ILiAD Biotechnologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ILiAD Biotechnologies \/ Inapplicable"},{"orgOrder":0,"company":"ILiAD Biotechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Bordetella Pertussis Vaccine, Live Attenuated","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"ILiAD Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"ILiAD Biotechnologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ILiAD Biotechnologies \/ Inapplicable"},{"orgOrder":0,"company":"ILiAD Biotechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Bordetella Pertussis Vaccine, Live Attenuated","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"ILiAD Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"ILiAD Biotechnologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ILiAD Biotechnologies \/ Inapplicable"},{"orgOrder":0,"company":"ILiAD Biotechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Bordetella Pertussis Vaccine, Live Attenuated","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"ILiAD Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"ILiAD Biotechnologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ILiAD Biotechnologies \/ Inapplicable"},{"orgOrder":0,"company":"ILiAD Biotechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Bordetella Pertussis Vaccine, Live Attenuated","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"ILiAD Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"ILiAD Biotechnologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ILiAD Biotechnologies \/ Inapplicable"},{"orgOrder":0,"company":"ILiAD Biotechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Bordetella Pertussis Vaccine, Live Attenuated","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"ILiAD Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"ILiAD Biotechnologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ILiAD Biotechnologies \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by ILiAD Biotechnologies

    Menu

    ILiAD Biotechnologies

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            ILiAD Biotechnologies

                            U.S.A arrow
                            Interphex
                            Not Confirmed

                            ILiAD Biotechnologies

                            U.S.A arrow
                            Interphex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bordetella Pertussis Vaccine, Live Attenuated

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Emmes Group

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            ILiAD Plans Collaboration with Emmes for Phase III Trials of Next-Gen Pertussis Vaccine

                            Details : ILiAD Collaboration with Emmes Group to advance the clinical development of BPZE1, which is being evaluated in the mid-stage clinical trial studies for the treatment of pertussis.

                            Product Name : BPZE1

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            July 06, 2024

                            Lead Product(s) : Bordetella Pertussis Vaccine, Live Attenuated

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Emmes Group

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            ILiAD Biotechnologies

                            U.S.A arrow
                            Interphex
                            Not Confirmed

                            ILiAD Biotechnologies

                            U.S.A arrow
                            Interphex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bordetella Pertussis Vaccine, Live Attenuated

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ILiAD Reports Positive Results in Phase 2b Trial of BPZE1 Pertussis Vaccine

                            Details : BPZE1 is a next-gen live-attenuated vaccine developed to block B. pertussis from colonizing the nasal passages of adults and children, to protect adults and children from whooping cough.

                            Product Name : BPZE1

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            May 28, 2024

                            Lead Product(s) : Bordetella Pertussis Vaccine, Live Attenuated

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            ILiAD Biotechnologies

                            U.S.A arrow
                            Interphex
                            Not Confirmed

                            ILiAD Biotechnologies

                            U.S.A arrow
                            Interphex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bordetella Pertussis Vaccine, Live Attenuated

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ILiAD Biotechnologies Reports First-ever Demonstration of Protection Against B. pertussis Colonization in Phas...

                            Details : BPZE1 is a next-generation live-attenuated pertussis vaccine designed to induce comprehensive and durable protection against B. pertussis infection (colonization) and disease (whooping cough).

                            Product Name : BPZE1

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            May 09, 2023

                            Lead Product(s) : Bordetella Pertussis Vaccine, Live Attenuated

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            ILiAD Biotechnologies

                            U.S.A arrow
                            Interphex
                            Not Confirmed

                            ILiAD Biotechnologies

                            U.S.A arrow
                            Interphex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bordetella Pertussis Vaccine, Live Attenuated

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ILiAD Biotechnologies Announces Presentation of Additional Positive Data for its Next Generation Pertussis Vac...

                            Details : BPZE1 is only next generation live-attenuated intranasal pertussis vaccine in clinical trials designed to protect against Bordetella pertussis nasal infection and active disease through induction of broad and sustained mucosal and systemic immunity.

                            Product Name : BPZE1

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            June 27, 2022

                            Lead Product(s) : Bordetella Pertussis Vaccine, Live Attenuated

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            ILiAD Biotechnologies

                            U.S.A arrow
                            Interphex
                            Not Confirmed

                            ILiAD Biotechnologies

                            U.S.A arrow
                            Interphex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bordetella Pertussis Vaccine, Live Attenuated,Azithromycin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Knott Partners

                            Deal Size : $42.8 million

                            Deal Type : Series D Financing

                            DEALS_DEV arrow-down

                            ILiAD Biotechnologies Announces $42.8M Financing Round to Advance BPZE1 Pertussis Vaccine

                            Details : BPZE1 is the most advanced next generation pertussis vaccine, designed to overcome deficiencies of current vaccines, including limited durability and the inability to prevent nasopharyngeal Bordetella pertussis infections that lead to transmission.

                            Product Name : BPZE1

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            June 09, 2022

                            Lead Product(s) : Bordetella Pertussis Vaccine, Live Attenuated,Azithromycin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Knott Partners

                            Deal Size : $42.8 million

                            Deal Type : Series D Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            ILiAD Biotechnologies

                            U.S.A arrow
                            Interphex
                            Not Confirmed

                            ILiAD Biotechnologies

                            U.S.A arrow
                            Interphex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tuberculosis Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : National Institutes of Health

                            Deal Size : $1.0 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            ILiAD Biotechnologies Receives NIH Grant to Develop Novel Tuberculosis Vaccine using proprietary B-Tech Vector...

                            Details : In addition to preclinical development of B-Tech Vector vaccines for TB and other targets, ILiAD continues to advance its BPZE1 pertussis vaccine through late-stage clinical development.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            April 26, 2022

                            Lead Product(s) : Tuberculosis Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : National Institutes of Health

                            Deal Size : $1.0 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            ILiAD Biotechnologies

                            U.S.A arrow
                            Interphex
                            Not Confirmed

                            ILiAD Biotechnologies

                            U.S.A arrow
                            Interphex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bordetella Pertussis Vaccine, Live Attenuated

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            FDA Grants ILiAD Biotechnologies Fast Track Designation for Next Generation Pertussis Vaccine BPZE1

                            Details : Fast Track Designation for BPZE1 is based on the positive topline results from Phase 2b trial demonstrating that BPZE1 induced durable mucosal immunity and reduced nasal colonization and, it has the potential to address unmet medical needs for such a dis...

                            Product Name : BPZE1

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            March 01, 2022

                            Lead Product(s) : Bordetella Pertussis Vaccine, Live Attenuated

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            ILiAD Biotechnologies

                            U.S.A arrow
                            Interphex
                            Not Confirmed

                            ILiAD Biotechnologies

                            U.S.A arrow
                            Interphex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bordetella Pertussis Vaccine, Live Attenuated

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ILiAD Biotechnologies Reports Preliminary Data Demonstrating Pertussis Vaccine Candidate BPZE1, but Not Boostr...

                            Details : BPZE1 is a live attenuated vaccine and next generation pertussis vaccine in advanced clinical trials which is designed to protect against Bordetella pertussis nasal infection and developed as a booster vaccine with future development investigating its ap...

                            Product Name : BPZE1

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            September 29, 2021

                            Lead Product(s) : Bordetella Pertussis Vaccine, Live Attenuated

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            ILiAD Biotechnologies

                            U.S.A arrow
                            Interphex
                            Not Confirmed

                            ILiAD Biotechnologies

                            U.S.A arrow
                            Interphex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bordetella Pertussis Vaccine, Live Attenuated

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ILiAD Biotechnologies Announces Upcoming Presentation at the European Society for Paediatric Infectious Diseas...

                            Details : Poster titled "Assessment Of Safety And Immunologic Responses Of BPZE1, An Intranasal Live Attenuated Pertussis Vaccine, In Healthy Adults" wil be presested at the conference.

                            Product Name : BPZE1

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            October 21, 2020

                            Lead Product(s) : Bordetella Pertussis Vaccine, Live Attenuated

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            ILiAD Biotechnologies

                            U.S.A arrow
                            Interphex
                            Not Confirmed

                            ILiAD Biotechnologies

                            U.S.A arrow
                            Interphex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bordetella Pertussis Vaccine, Live Attenuated

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ILiAD Biotechnologies Reports Positive Topline Results from Phase 2b Trial for Pertussis Vaccine Candidate BPZ...

                            Details : BPZE1 prevented colonization from re-vaccination/challenge in 90% of subjects with no vaccine related serious adverse events.

                            Product Name : BPZE1

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            September 29, 2020

                            Lead Product(s) : Bordetella Pertussis Vaccine, Live Attenuated

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth